$186.84
-1.43(-0.76%)
Mkt Cap $11.5B
$97.78
$196.83
52-Week Range
At A Glance
1
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internation...
2
Revenue is primarily driven by Product And Services Product Sales Net Of Deductions (32.3%) and Total Neuroscience (23.1%).
3
Most recently: and in the Press Release furnished as Exhibit 99.1 to this current report shall not be incorporated by reference into any filing with the U.S. Securities and Ex (2026-02-24).
$11.5B
Market Cap
$4.3B
Revenue
-$360M
Net Income
Employees2,800
Fundamentals
How The Business Makes Money
Revenue by Segment
Product And Services Product Sales Net Of Deductions32.3%($11.6B)
Total Neuroscience23.1%($8.3B)
Xywav12.3%($4.4B)
Total Oncology9.1%($3.3B)
Epidiolex Epidyolex8%($2.9B)
Rylaze Enrylaze3.4%($1.2B)
Xyrem2.6%($950M)
Zepzelca2.6%($917M)
Defitelio Defibrotide1.7%($600M)
Product And Services Royalties And Contract Revenue1.6%($591M)
High Sodium AG Oxybate Product Royalty Revenue1.4%($505M)
Vyxeos1.3%($457M)
Other Royalties And Contract Revenue0.2%($86M)
Sativex0.2%($55M)
Modeyso0.1%($48M)
Other Products0.1%($39M)
Ziihera0.1%($26M)
Revenue by Geography
US90.2%($11.0B)
Europe7.6%($923M)
Other Countries2.2%($266M)
Activity
What Changed Recently
Company Profile
CIK0001232524
ISINIE00B4Q5ZN47
CUSIPG50871105
Phone353 1 634 7800
AddressWaterloo Exchange, Dublin, 4, IE
SEC EDGAR